AscellaHealth Ranks Third on Philadelphia Business Journal’s 2024 Fast 50 List of Fastest-Growing Companies

BERWYN, Pa., October 03, 2024–(BUSINESS WIRE)–AscellaHealth, a global partner delivering customizable solutions to support the specialty pharmaceutical industry, announces the Company has been identified as one of the region’s fastest-growing companies. List makers are required to be headquartered in Greater Philadelphia, be independently owned without a parent company, have sustained revenue growth from 2021-2023 and a minimum revenue of $750,000 in 2021.

“This recognition highlights the significant value we provide to the global life sciences and healthcare industry as we expand our international presence and drive business growth,” says Dea Belazi, CEO, AscellaHealth. “As a trusted partner in the specialty pharmaceutical industry, we attribute our outstanding achievements to the commitment, expertise and efforts of our entire organization. Every day, our dedicated professional teams focus on patient care, enabling AscellaHealth to effectively deliver essential healthcare products from manufacturers to patients while ensuring an efficient flow of funds between payers and pharmaceutical companies.”

Each year the Philadelphia Business Journal sets out to recognize Greater Philadelphia’s fastest-growing companies based on average two-year revenue growth. Formerly known as Soaring 76, the Business Journal rebranded the program this year to Philly’s Fast 50, which puts the emphasis on private companies. This marks AscellaHealth’s fourth time on the list.

To determine the list, the Business Journal sought online nominations from private companies. Those that met this year’s parameters were then vetted through a process that included the Business Journal editorial board and the accounting partner for this year, CLA. In a nod to the program’s roots, a single spot was reserved on this year’s list for the region’s fastest-growing public company.

“As a leading global specialty pharmaceutical provider, AscellaHealth is dedicated to advancing its patient-centered care model and shows a strong commitment to creating innovative solutions and programs that deliver unique value to our clients, partners and patients,” says Bill Oldham, chairman and president of AscellaHealth. “Our continuous corporate growth focuses on enhancing clinical outcomes for patients with complex, chronic conditions and rare diseases while also addressing the needs of payers and health plans for more effective management of medical and pharmacy costs. Our impressive revenue growth of 746.1% over the past three years reflects our success in the industry.”

About AscellaHealth LLC

AscellaHealth is a global partner that delivers proven end-to-end solutions to both life sciences and healthcare companies to enhance the quality of life for patients with complex, chronic conditions. A dedicated team gets critical healthcare products from manufacturers to patients while ensuring an efficient flow of funds between payers and pharma. Visit www.AscellaHealth.com.

About Philadelphia Business Journal

The Philadelphia Business Journal is the premier media solutions platform for companies strategically targeting business decision makers. The media products provide comprehensive coverage of business news from a local, regional, and national perspective publishing daily stories on its website, social networks, and weekly edition available in print and online. The Philadelphia Business Journal is part of American City Business Journals (ACBJ) that delivers a total business audience of over 10 million people via our websites and publications and nearly 1,000 annual industry leading events. ACBJ owns 44 business publications across the country that offers exclusive, in-depth business coverage.

In addition, ACBJ owns and operates AmericanInno, BizWomen, BizEquity and Hemmings. ACBJ is a unit of Advance Publications, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241003434375/en/

Contacts

Media:
Nicole Dufour
CPR Communications
ndufour@cpronline.com
201.641.1911 x 54